Stefan Schreiber, ECCO-IBD 2022: Filgotinib in Ulcerative Colitis: A Post Hoc Analysis of the SELECTION Trial
We were delighted to talk to Prof. Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, Germany) around his post hoc analysis of the SELECTION trial, investigating filgotinib in Ulcerative Colitis.
The abstract ‘Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial’ (Presentation no. OP07) was presented at the 17th Congress of ECCO, February 16-19, 2022!
- How are therapeutic goals evolving in the management of patients with UC? (0:16)
- Could you give us a brief overview of the SELECTION trial and its findings? (1:21)
- What were the aims of your post-hoc analysis of the SELECTION trial data and how well was the composite endpoint achieved? (2:19)
- What will be the impact of these findings on future clinical trial design? (4:28)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Amgen, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, Provention Bio, Protagonist, Falk, Ferring, UCB, Sandoz/Hexal, Lilly & Galapagos.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual meeting 2022.
Share this Video
Related Videos In Digestive Disorders
UEG Digestive Health Month: Matthias Löhr, May 2023
Digestive Health Month took place over May 2023 to raise awareness of digestive diseases and cancers, which often remain overlooked in terms of policy, funding and research in Europe. We were delighted to talk with UEG’s Vice President Prof. Matthias Löhr (Karolinska Institutet, Stockholm, Sweden) around the public health and economic burden of digestive diseases, […]
Stefan Schreiber, ECCO’23: Corticosteroid-free remission with etrasimod in ulcerative colitis – analysis of the ELEVATE UC 52 study
The ELEVATE UC 52 study (NCT03945188) investigated the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis, a recent analysis of the study was presented at ECCO’23 looking at corticosteroid (CS)-free remission as a clinical endpoint. In this touchIMMUNOLOGY interview, we spoke with Dr. Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, […]
Stefan Schreiber, ECCO’23: Current treatment paradigm for ulcerative colitis and corticosteroid-free remission as a treatment goal
The current treatment paradigm for ulcerative colitis (UC) includes amino salicylic acid as a first line treatment followed by corticosteroids, targeted treatment and rectal topical therapy; however, with corticosteroids (CS) impacting long-term health, CS-free remission has become a long-term goal in treatment. Etrasimod is an S1P receptor modulator, recently investigated for the treatment of UC […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!